2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Epcoritamab: new trials by email Literature Review of Epcoritamab trials Research Report on Epcoritamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma Epcoritamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Genmab | 111 | 2023-03-06 | 2026-10-23 |
| First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 46 | 2020-03-13 | 2024-10-24 |
Lymphoma, Large B-Cell, Diffuse (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1)
Genmab (2)
Belgium (2) · Spain (2) · United States (2) · Austria (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1) · South Korea (1) · United Kingdom (1)
2019 (1), 2023 (1)